Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1983 Dec;16(2):98–100. doi: 10.1007/BF00199239

Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

Ian R Mackay 1,, Michael D E Goodyear 1, Clare Riglar 1, Jennifer Penschow 1
PMCID: PMC11039202  PMID: 6420047

Abstract

Natural killer (NK) cell activity and antibody-dependent (K) cell activity were studied sequentially in 30 patients with early node-positive breast cancer entered into an adjuvant chemotherapy trial. The drugs used were melphalan, and melphalan with methotrexate, given for 12 months. Estimations were made 3-monthly during chemotherapy, and then at 15 and 24 months to assess recovery. Mean values for NK-cell activity during chemotherapy were significantly lower than the mean pre-chemotherapy baseline value at all time-points from 3 to 15 months, but there was recovery by 24 months. Mean values for K-cell activity during chemotherapy did not appear to differ from the mean pre-chemotherapy value, but variability in individual values was high. Over a 4-year follow-up period, a comparison of 16 patients who did not develop recurrent breast cancer with 14 who did showed that NK-cell activity was significantly lower in the latter group 12 months after the start of chemotherapy.

Keywords: Breast Cancer, Natural Killer, Methotrexate, Melphalan, Cell Activity

References

  • 1.Bonadonna G, Valagussa P, Rossi A, Zucali R, Tancini G, Bajetta E, Brambilla C, De Lena M, Di Fronzo G, Banfi A, Rilke F, Veronesi U. Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol. 1978;5:450. [PubMed] [Google Scholar]
  • 2.Cunningham-Rundles S, Filippa DA, Braun DW, Antonelli P, Ashikari H. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst. 1981;67:585. [PubMed] [Google Scholar]
  • 3.Eremin O. NK cell activity in the blood, tumour-draining lymph nodes and primary tumours of women with mammary carcinoma. In: Herberman RB, editor. Natural cell-mediated immunity against tumors. New York: Academic Press; 1980. pp. 1011–1029. [Google Scholar]
  • 4.Fisher B, Sherman B, Rockette H, Redman C, Margolese R, Fisher ER. L-phenyl alanine mustard (L-PAM) in the management of pre-menopausal patients with primary breast cancer. Lack of depression of disease-free survival with depression of ovarian function. Cancer. 1979;44:847. doi: 10.1002/1097-0142(197909)44:3<847::aid-cncr2820440309>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  • 5.Forbes JT, Greco FA, Oldham RK. Human natural cell-mediated cytotoxicity. II. Levels in neoplastic disease. Cancer Immunol Immunother. 1981;11:147. [Google Scholar]
  • 6.Goodyear MDE, Mackay IR, Russell IS. Delayed recovery of peripheral blood cell numbers after adjuvant cytotoxic chemotherapy for Stage II breast cancer. Cancer Chemother Pharmacol. 1981;7:37. doi: 10.1007/BF00258211. [DOI] [PubMed] [Google Scholar]
  • 7.Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res. 1978;27:305. doi: 10.1016/s0065-230x(08)60936-7. [DOI] [PubMed] [Google Scholar]
  • 8.Herberman RB, Ortaldo JR. Natural killer cells: their role in defenses against disease. Science. 1981;214:24. doi: 10.1126/science.7025208. [DOI] [PubMed] [Google Scholar]
  • 9.Mackay IR, Goodyear MDE, Riglar C, Penschow J, Whittingham S, Russell IS, Kitchen PRB, Collins JP (1984) Effect on immunological and other indices of adjuvant cytotoxic chemotherapy in breast cancer. Cancer (in press) [DOI] [PubMed]
  • 10.McCredie JA, MacDonald HR. Antibody-dependent cellular cytotoxicity in cancer patients: lack of prognostic value. Br J Cancer. 1980;41:880. doi: 10.1038/bjc.1980.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery. 1978;83:492. [PubMed] [Google Scholar]
  • 12.Penschow J, Mackay IR. NK and K cell activity of human blood: differences according to sex, age, and disease. Ann Rheum Dis. 1980;39:82. doi: 10.1136/ard.39.1.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pross HF, Baines MG. Studies of natural human killer cells. In vivo parameters affecting normal cytotoxic function. Int J Cancer. 1982;29:383. doi: 10.1002/ijc.2910290404. [DOI] [PubMed] [Google Scholar]
  • 14.Saijo N, Shimizu E, Shibuya M, Irimajiri N, Takizawa T, Eguchi K, Shinkai T, Tominaga K, Shimabukuro Z, Tanaguchi T, Hoshi A. Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung. B J Cancer. 1982;46:180. doi: 10.1038/bjc.1982.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Strender L-E, Blomgren H, Petrini B, Wasserman J, Fosgren M, Norberg R, Boral E, Wallgren A. Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer. 1981;48:1996. doi: 10.1002/1097-0142(19811101)48:9<1996::aid-cncr2820480915>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  • 16.Uchida A, Kolb R, Micksche M. Generation of suppressor cells for natural killer activity in cancer patients after surgery. J Natl Cancer Inst. 1982;68:735. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES